Novo Nordisk has announced that the Food and Drug Administration (FDA) has approved semaglutide (Ozempic) to reduce the risk ...

The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Results from a case series identified a potential association between ophthalmic complications and the rapid correction of hyperglycemia, brought on by patients using either semaglutide or tirzepatide ...

New Delhi: Sun Pharma Labs has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug ...

Semaglutide (known by its brandname Ozempic) has gained widespread attention for its weight loss benefits, but is officially ...

A healthcare provider can help you determine whether Rybelsus (semaglutide ... 2 mg per 3 milliliters (mL), 2 mg/1.5 mL, 4 mg ...

Female sex, antidepressant use, and type of health insurance significantly influence semaglutide initiation. (HealthDay News) — Sociodemographic, health care, and clinical factors are associated with ...

This is particularly relevant for semaglutide, given the possibility ... Partial evaporation was allowed (until at least 1 ml ...